**Candida SPP. ANTIFUNGAL SUSCEPTIBILITY PROFILE OF CLINICAL ISOLATES OF DENTAL PROSTHESIS USERS**

Simone K. Ferrão¹, Juliana Butzge³, Miriam Apel³, Luciana Calil¹, Adelina Mezzari¹ and Renata P. Limberger²

¹BioMicoLab – Mycology Laboratory; ²LabToxico – Toxicology Laboratory, ³Pharmacognosy Laboratory; Pharmacy Faculty, UFRGS, RS, Brazil. *siferrao@hotmail.com

### INTRODUCTION

Candidiasis is an opportunistic mycosis caused by yeasts of the *Candida* genus, which is part of the human microflora⁴. Several factors may predispose the development of oral candidiasis, such as xerostomia, immunosuppression, and the use of dental prostheses. The main epidemiology factors of Candidiasis depends on the predisposition of the host, parasitic loading and fungal virulence⁵. In general, the treatment of oral candidiasis uses nystatin as the first choice². When this medicine is not good enough, the use of fluconazole and itraconazole can be employed⁶. However, in recent decades, there has been a great increase in resistance to the antifungal agents used in therapeutic practice. This justifies the necessity of prospecting for new antifungal agents⁷. In this way, essential oils from plants represent an important renewable source with potential against resistant strains³.

### MATERIAL AND METHODS

Clinical isolates were identified by MALDI-TOF MS Biotyper 4.0 microflex Bruker. The antifungal susceptibility tests were made by the broth microdilution assay according to the methodology M-27 A2 recommended by the National Committee for Clinical Laboratory Standards, being testing the following antifungals: nystatin, fluconazole, itraconazole, and the essential oils of *Pelargonium graveolens* (geraniaceae), *Cinnamomum cassia* (cinnamon - Lauraceae), *Syzygium aromaticum* (clove - Myrtaceae) and *Myristica fragrans* (nutmeg - Myristicaceae) Ethical approval 2.236.863, CEP-UFRGS.

### RESULTS

The antifungal susceptibility profile showed the following Minimum Inhibitory Concentration (MIC) results: fluconazole (MIC 0.5 - 32 µg/ml), itraconazole (MIC 0.125 – 4 µg/ml), nystatin (MIC 0.5 - 1 µg/ml) for *C. albicans* fluconazole (MIC 16 µg/ml), itraconazole (MIC 2 µg/ml), nystatin (MIC 0.5 µg/ml) for *C. lusitaniae*. All essential oils evaluated showed positive effects against the *Candida* species evaluated. The best results obtained with essential oil from cinnamon (MIC 15.60 - 31.25 µg/ml), followed by oils from clove (MIC 62.50 – 125 µg/ml), geranium (MIC 62.50 – 125 µg/ml) and nutmeg oil (MIC 250 – 500 µg/ml).

### CONCLUSIONS

Cinnamon and clove showed promising potential for use in the oral candidiasis treatment. More studies are in course, as the essential oils chemical composition by GC/MS and biofilm formation capacity of *Candida* spp.

### ACKNOWLEDGMENTS

Financial support from FAPERGS, CAPES and CNPq/Brazil

### REFERENCES